Company intelligence / Profile preview
BioCytics
- Ownership
- Private
- Employees
- ~30
- Development stage
- Preclinical
Overview
BioCytics is developing autologous immune cell therapies for solid tumor cancers. Their lead program, BCyIF1, is advancing toward IND submission with support from a ScaleReady G-Rex grant to optimize cGMP manufacturing. The company collaborates on translational research and biospecimen banking but has not yet initiated patient infusions or received FDA approval for its products.
- Therapeutic areas
- Oncology
- Modalities
- Autologous immune cell therapiesCellular therapies (immune cell fractions)
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on BioCytics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioCytics.